Investigated for use/treatment in adenomatous polyposis coli, lung cancer, prostate cancer, colon polyps, Barrett's esophagus disease, and pediatric indications.
- Mechanism
- Curator reviewed
Exisulind is a sulindac derivative of a class of compounds called selective apoptotic anti-neoplastic drugs (SAANDs), which inhibit the enzyme cyclic guanosine monophosphodiesterase (cGMP - PDE). Exisulind is specific for apoptotic effects in precancerous and cancerous colorectal cells due to their overexpression of cGMP. Sustained elevation of cGMP and protein kinase G (PKG) activation may be also implicated in the induction of apoptosis by Exisulind.
- Primary indication
- Investigated for use/treatment in adenomatous polyposis coli, lung cancer, prostate cancer, colon polyps, Barrett's esophagus disease, and pediatric indications.Curator reviewed
- Formula / weight
- C20H17FO4S · 372.41 g/mol (avg)
- Also known as
- Sulindac sulfone
- Code names
- FGN 1
Resolves to
MVGSNCBCUWPVDA-MFOYZWKCSA-NSMILESCC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(C=C1)S(C)(=O)=OWhat you can answer from here — as of January 29, 2025
Which drugs share a target with Exisulind, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account